Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, appointed Neil Gallagher president, head of research and development (R&D), effective April 10, 2023. Gallagher brings more than 20 years of industry experience, most recently serving as chief medical officer, vice president, head of development at AbbVie, where he led multiple development programs through approval and oversaw asset strategy and portfolio management ac...